Exhibit 99.1 Psyence Biomedical Ltd. Unaudited Condensed Consolidated Interim Financial Statements For the three and six months ended September 30, 2025 and 2024 Expressed in United States Dollars (USD $) PSYENCE BIOMEDICAL LTD. Condensed Consolidated Interim Financial Statements (unaudited) Condensed Consolidated Interim Statements of Financial Position As at September 30, 2025 and March 31, 2025 | | | As at | As at | | --- | --- | --- | --- | | | | September 30, | March 31, | | | | 2025 | 2025 | | USD $ | ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Mobile-Network Solutions (MNDR) is up 96% at $3.26 - PACS Group, Inc. (PACS) is up 44% at $24.37 - Cerence Inc. (CRNC) is up 28% at $10.16 - Magnera Corporation (MAGN) is up 26% at $10.07 - Oddity Tech Ltd. (ODD) is up 17% at $43.75 - Allot Ltd. (ALLT) is up 14% at $9.80 - Artiva Biotherapeutics, Inc. (ARTV) is up 14% at $3.88 - Kulicke and Soffa Industries, Inc. (KLIC) is up 13% at $40.22 - Fossil Group, Inc. (FOSL) is up 12% at $2.29 - NVIDIA Corporation (NVDA) is up 5% at $195.84 [3] Premarket Losers - Brera Holdings PLC (SLMT) is down 33% at $3.84 - Bath & Body Works, Inc. (BBWI) is down 14% at $18.04 - Cemtrex, Inc. (CETX) is down 11% at $3.20 - Atkore Inc. (ATKR) is down 9% at $60.00 - Gloo Holdings, Inc. (GLOO) is down 9% at $7.30 - SMX (Security Matters) Public Limited Company (SMX) is down 9% at $4.60 - Sonim Technologies, Inc. (SONM) is down 8% at $7.31 - Psyence Biomedical Ltd. (PBM) is down 7% at $2.56 - MMTec, Inc. (MTC) is down 6% at $2.00 - Ridgetech, Inc. (RDGT) is down 5% at $4.78 [4]

Core Viewpoint - Psyence Biomedical Ltd. has established a sustainable supply of high-potency iboga bark through its partnership with PsyLabs, which is crucial for the clinical development of ibogaine for substance use disorders [1][2][4] Group 1: Supply Chain and Product Development - The collaboration with PsyLabs ensures a long-term supply of GMP-compliant ibogaine, with the first 50 kg received and being processed into pharmaceutical-grade ibogaine HCL and Total Alkaloid Extracts [2][3] - The company is committed to ethical sourcing and sustainability, ensuring that ibogaine and related alkaloids are derived from Tabernanthe iboga and Voacanga africana while respecting cultural traditions and benefiting source communities [3][4] Group 2: Strategic Positioning and Market Leadership - The establishment of a reliable and ethically sourced supply chain positions Psyence BioMed as a leader in the emerging ibogaine sector, enhancing its competitive advantage as international interest in ibogaine grows [4] - The company aims to set a new standard for ethical psychedelic production, emphasizing partnerships with traditional knowledge holders rather than treating them merely as suppliers [4][6] Group 3: Company Overview - Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine-based psychedelic medicine, addressing unmet mental health needs [6] - The company is the first life sciences biotechnology firm specializing in psychedelic therapeutics to be listed on Nasdaq, reflecting its commitment to an evidence-based approach in developing safe and effective treatments [6]

Core Viewpoint - Psyence BioMed is positioned as the only publicly listed psychedelics company with active operations and manufacturing capabilities in Africa, enhancing its access to ibogaine, a compound derived from the Tabernanthe iboga shrub, which is crucial for developing therapies for mental health needs [1][2]. Company Overview - Psyence BioMed focuses on nature-derived psilocybin and ibogaine therapies to address unmet mental health needs, particularly in palliative care [10]. - The company has established a strategic investment in PsyLabs, which operates a GMP-compliant facility in Southern Africa, producing highly purified psychedelic compounds [3][9]. Strategic Positioning - By operating at the source of ibogaine, Psyence BioMed can ensure sustainable and responsible access to this compound, allowing for quality control from cultivation to finished product [2][3]. - The vertical integration of Psyence BioMed's operations strengthens supply security and scalability, positioning the company favorably within the psychedelics sector [3][8]. Market Trends - There is a global surge in interest and research surrounding ibogaine as a potential treatment for addiction and mental health disorders, with significant findings indicating its effectiveness in reducing PTSD symptoms among veterans [4][5]. - The State of Texas has allocated $50 million for clinical research on ibogaine, aiming to develop FDA-approved treatments for opioid use disorder, which reflects growing governmental support for psychedelic medicine [5]. Industry Developments - Major pharmaceutical companies, such as AbbVie, are increasingly investing in psychedelic compounds, highlighting the clinical potential of ibogaine and its analogs [6][7]. - Psyence BioMed is actively engaged in developing next-generation analogs of ibogaine, aligning with the industry's shift towards innovative therapeutic solutions [6][8]. Supply Chain and Compliance - PsyLabs is federally licensed to cultivate and export various psychedelic compounds, ensuring compliance with safety and traceability standards [9][10]. - The company's operations are supported by an ISO 22000-certified facility, emphasizing its commitment to high safety standards and regulatory compliance [10].

Core Insights - Psyence Biomedical Ltd. has achieved a significant clinical milestone by successfully dosing multiple patients in its Phase IIb clinical trial for nature-derived psilocybin as a treatment for Adjustment Disorder in palliative care [1][2][5] Company Overview - Psyence Biomedical Ltd. is a biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, particularly in palliative care [7] - The company is recognized as a global leader in late-stage psychedelic drug development and is the first life sciences biotechnology company specializing in this area to be listed on Nasdaq [2][7] Clinical Trial Details - The Phase IIb study is designed to meet regulatory expectations and includes a larger sample size, rigorous randomization, and a multi-site structure to enhance data reliability and generalizability [3][5] - The trial aims to enroll 87 patients across Australia, with participants receiving either 10 mg or 25 mg of psilocybin or a low-dose comparator of 1 mg, alongside structured psychotherapy [5] - The study will assess the efficacy, safety, and durability of response to psilocybin as a potential first-in-class treatment for Adjustment Disorder in palliative care settings [5][6] Operational Readiness - Patients have been dosed at two active clinical sites in Australia, with plans to expand to a third site to accelerate data collection, with topline results expected by the end of 2026 [4][6] - The operational readiness and recruitment efficiency of the company have been highlighted as key strengths in executing the trial [4][6]

Core Insights - Psyence Biomedical Ltd. has made a follow-on investment of USD 3,500,000 in PsyLabs, enhancing its supply chain for psychedelic compounds [1][2] - This investment follows a previous investment of USD 500,000 in April 2025, indicating a strong commitment to securing high-quality, GMP-grade psychedelic ingredients [2][3] - The CEO of Psyence BioMed emphasized the strategic importance of this investment in building a fully integrated company focused on sustainable and scalable production [3] Company Overview - Psyence Biomedical Ltd. is a biopharmaceutical company specializing in nature-derived psilocybin and ibogaine therapies aimed at addressing unmet mental health needs [7] - It is the first life sciences biotechnology company focused on developing non-synthetic psychedelic medicine to be listed on Nasdaq [7] - The company aims to create safe, effective, and FDA-approved treatments for a range of mental health disorders [7] Partnership and Production - PsyLabs is recognized as a leading producer of purified psychedelic active pharmaceutical ingredients (APIs) and is federally licensed to cultivate and export various psychedelic compounds [9] - The partnership between Psyence BioMed and PsyLabs is strengthened through this investment, positioning Psyence as a leader in the emerging psychedelic therapeutics sector [5] - PsyLabs operates a state-of-the-art facility in Southern Africa, utilizing the region's botanical heritage under strict ethical and sustainable practices [4][10] Strategic Goals - The investment aims to secure a reliable supply of premium psychedelic compounds for Psyence BioMed's clinical research programs, ensuring long-term value for investors [2][3] - The company is focused on building a responsible global supply chain, which is crucial for advancing its clinical pipeline and commercial opportunities [3][5]

As filed with the Securities and Exchange Commission on October 14, 2025 Registration No. 333-289285 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to Form F-3 on Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Psyence Biomedical Ltd. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) Ontario, Canada 2834 Not Applicable (Primary Standard Industrial Classification Code Number) (I.R.S. ...

As filed with the Securities and Exchange Commission on October 6, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to Form F-3 on Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Psyence Biomedical Ltd. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation or Organization) Ontario, Canada 2834 Not Applicable (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Numbe ...

Group 1: Super League Enterprise, Inc. - Super League Enterprise, Inc. announced a $10 million strategic equity investment from Evo Fund, leading to a sharp increase in its stock price [1] - Shares of Super League Enterprise rose 200% to $9.83 in pre-market trading following the announcement [1] Group 2: Other Notable Gainers - Professional Diversity Network, Inc. gained 88.8% to $5.40 in pre-market trading after a previous rise of around 4% [4] - STRATA Skin Sciences, Inc. rose 80% to $3.06 in pre-market trading after an 8% increase on Monday [4] - Jiuzi Holdings, Inc. jumped 50.9% to $1.69 in pre-market trading after a 5% gain on Monday [4] - New Era Energy & Digital, Inc. gained 47.2% to $0.8941 in pre-market trading after a surge of around 12% on Monday [4] - Better Home & Finance Holding Company increased by 30% to $64.95 in pre-market trading, following a 46% jump on Monday [4] - MicroCloud Hologram Inc. surged 29% to $7.17 in pre-market trading after announcing a breakthrough in quantum technology [4] - Cassava Sciences, Inc. rose 24.1% to $2.88 in pre-market trading after CEO Richard Barry purchased shares at an average price of $2.25 [4] - SES AI Corporation surged 10.3% to $2.04 in pre-market trading after a 17% increase on Monday [4] - Ballard Power Systems Inc. gained 8.3% to $3.12 in pre-market trading after a 5% rise on Monday [4] Group 3: Notable Decliners - Psyence Biomedical Ltd. dipped 19.6% to $3.65 in pre-market trading after a decline of around 5% on Monday [4] - Diginex Limited shares fell 17.7% to $14.60 in pre-market trading after a jump of over 30% on Monday [4] - Addentax Group Corp. declined 16.5% to $0.9021 in pre-market trading after gaining more than 30% on Monday [4] - Boxlight Corporation fell 15.5% to $4.03 in pre-market trading after a significant jump of 205% on Monday [4] - Reliance Global Group, Inc. dropped 15.5% to $0.9122 in pre-market trading after a 47% increase on Monday [4] - Qualigen Therapeutics, Inc. declined 14.1% to $4.75 in pre-market trading after a 95% jump on Monday [4] - Fly-E Group, Inc. fell 13.1% to $0.8773 in pre-market trading after announcing a securities purchase agreement [4] - Firefly Aerospace Inc. dropped 12.5% to $43.29 in pre-market trading after reporting a second-quarter loss [4] - Opendoor Technologies Inc. dipped 6.3% to $7.85 in pre-market trading after a 12% fall on Monday [4] - Symbotic Inc. fell 4.8% to $57.80 in pre-market trading after a gain of more than 6% on Monday [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - 89bio, Inc. (ETNB) increased by 83% to $14.84 [3] - Aptevo Therapeutics Inc. (APVO) rose by 75% to $2.47 [3] - Psyence Biomedical Ltd. (PBM) saw a 29% increase to $4.82 [3] - Beam Global (BEEM) gained 27% reaching $3.23 [3] - MicroAlgo Inc. (MLGO) was up 14% at $13.06 [3] - Akero Therapeutics, Inc. (AKRO) increased by 12% to $47.50 [3] - Hyperion DeFi, Inc. (HYPD) rose by 11% to $13.69 [3] - Sonnet BioTherapeutics Holdings, Inc. (SONN) increased by 11% to $7.85 [3] - FuelCell Energy, Inc. (FCEL) was up 9% at $8.34 [3] - Robo.ai Inc. (AIIO) gained 6% to $2.05 [3] Premarket Losers - Presidio Property Trust, Inc. (SQFT) decreased by 14% to $7.58 [4] - Aeluma, Inc. (ALMU) fell by 10% to $15.18 [4] - FGI Industries Ltd. (FGI) dropped 10% to $7.65 [4] - Lazydays Holdings, Inc. (GORV) was down 9% at $2.26 [4] - StableX Technologies, Inc. (SBLX) decreased by 8% to $5.40 [4] - Artelo Biosciences, Inc. (ARTL) fell by 8% to $4.48 [4] - SciSparc Ltd. (SPRC) decreased by 8% to $4.10 [4] - Cracker Barrel Old Country Store, Inc. (CBRL) was down 7% at $45.75 [4] - Columbus Circle Capital Corp I (BRR) fell by 7% to $9.42 [4] - Visionary Holdings Inc. (GV) decreased by 7% to $2.58 [4]